Quality control of gold nanoparticles as pharmaceutical ingredients.

Fiche publication

Date publication

octobre 2019

Journal

International journal of pharmaceutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROUX Stéphane

Tous les auteurs :
Pallotta A, Boudier A, Creusot B, Brun E, Sicard-Roselli C, Bazzi R, Roux S, Clarot I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31376468

Résumé

Nanoparticles are being developed for a wide range of medical applications such as, controlled release, drug delivery systems or imagery, theranostics, implants…. For the moment, there is no legal definition of nanoparticles or nanomaterials for therapeutic use. The specific case of gold nanoparticles is not an exception: their current definition as nanoparticle material does not correspond to classic pharmaceutical ingredients as described in Pharmacopoeias. In this study, more than 30 different batches of citrate stabilized gold nanoparticles (AuNP) were synthesized and analyzed thanks to both classical approaches (UV-Vis spectrophotometry, dynamic light scattering coupled or not to electrophoresis …) and capillary zone electrophoresis (CZE) coupled to diode array detection to assess their purity and impurity profiles. These techniques led to the beginning of defined specifications, a key step for the use of gold nanoparticles as pharmaceutical ingredients. CZE was demonstrated suitable to evaluate a batch-to-batch quality control, to monitor the purification processes and to follow the stability of 18 different batches for 20 days. Finally, commercially available AuNP samples were tested and the results compared to the provided certificates of analysis.